Recap: Enanta Pharmaceuticals Q1 Earnings


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat in after-market trading after the company reported Q1 results.

Quarterly Results

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Earnings per share decreased 163.08% year over year to ($0.41), which beat the estimate of ($0.74).

Revenue of $31,743,000 declined by 39.62% from the same period last year, which beat the estimate of $28,790,000.

Outlook

Enanta Pharmaceuticals hasn't issued any earnings guidance for the time being.

Enanta Pharmaceuticals hasn't issued any revenue guidance for the time being.

Conference Call Details


FREE REPORT: How To Learn Options Trading Fast

In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, ​a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.


Date: Feb 08, 2021

Time: 04:30 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.enanta.com%2F&eventid=2947516&sessionid=1&key=9E656BA22915EB0B1659FBCED981AF9B®Tag=&V2=false&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $58.59

52-week low: $38.40

Price action over last quarter: Up 28.12%

Company Overview

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: EarningsBZI-Recaps